메뉴 건너뛰기




Volumn 12, Issue 8, 2005, Pages 588-601

Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: Expert opinions based on the Proceedings of an International Consensus Conference

Author keywords

Interferon beta; Multiple sclerosis; Neutralizing antibodies to interferon beta

Indexed keywords

ADENOSINE DEAMINASE; ALPHA INTERFERON; ALPHA2 INTERFERON; ANTIBODY; ANTIERYTHROPOIETIN ANTIBODY; BETA 2 MICROGLOBULIN; BETA INTERFERON; BETA1A INTERFERON; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CHORIONIC GONADOTROPIN; DENILEUKIN DIFTITOX; ERYTHROPOIETIN; GONADORELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; INSULIN; INSULIN ANTIBODY; INTERFERON BETA SERINE; INTERLEUKIN 3; MYXOVIRUS RESISTANCE PROTEIN A; NEOPTERIN; NEUTRALIZING ANTIBODY; RECOMBINANT ERYTHROPOIETIN; SALCATONIN; STAPHYLOKINASE; STREPTOKINASE; UNCLASSIFIED DRUG;

EID: 23644433705     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2005.01104.x     Document Type: Conference Paper
Times cited : (43)

References (80)
  • 1
    • 0032871741 scopus 로고    scopus 로고
    • Development of antibodies to interferon beta in patients: Technical and biological aspects
    • Antonelli G, Dianzani F (1999). Development of antibodies to interferon beta in patients: technical and biological aspects. Eur Cytokine Netw 10:413-422.
    • (1999) Eur Cytokine Netw , vol.10 , pp. 413-422
    • Antonelli, G.1    Dianzani, F.2
  • 2
    • 9044230923 scopus 로고    scopus 로고
    • Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-α2 therapy
    • Antonelli G, Giannelli G, Currenti M et al. (1996). Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-α2 therapy. Clin Exp Immunol 104:384-387.
    • (1996) Clin Exp Immunol , vol.104 , pp. 384-387
    • Antonelli, G.1    Giannelli, G.2    Currenti, M.3
  • 3
    • 0031978274 scopus 로고    scopus 로고
    • Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a
    • Antonelli G, Bagnato F, Pozzilli C et al. (1998). Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β1a. J Interferon Cytokine Res 18:345-350.
    • (1998) J Interferon Cytokine Res , vol.18 , pp. 345-350
    • Antonelli, G.1    Bagnato, F.2    Pozzilli, C.3
  • 4
    • 0032858799 scopus 로고    scopus 로고
    • Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a and IFN beta-1b
    • Antonelli G, Simeoni E, Bagnato F et al. (1999). Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a and IFN beta-1b. J Neurol Sci 168:131-136.
    • (1999) J Neurol Sci , vol.168 , pp. 131-136
    • Antonelli, G.1    Simeoni, E.2    Bagnato, F.3
  • 6
    • 0034691518 scopus 로고    scopus 로고
    • Interferon β neutralizing antibodies in multiple sclerosis: Neutralizing activity and cross-reactivity with three different preparations
    • Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R (2000). Interferon β neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 48:95-100.
    • (2000) Immunopharmacology , vol.48 , pp. 95-100
    • Bertolotto, A.1    Malucchi, S.2    Milano, E.3    Castello, A.4    Capobianco, M.5    Mutani, R.6
  • 7
    • 0036329631 scopus 로고    scopus 로고
    • Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: A follow up study in an independent laboratory
    • Bertolotto A, Malucchi S, Sala A et al. (2002). Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73:148-153.
    • (2002) J Neurol Neurosurg Psychiatry , vol.73 , pp. 148-153
    • Bertolotto, A.1    Malucchi, S.2    Sala, A.3
  • 8
    • 0037465461 scopus 로고    scopus 로고
    • Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients
    • Bertolotto A, Gilli F, Sala A et al. (2003). Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology 60:634-639.
    • (2003) Neurology , vol.60 , pp. 634-639
    • Bertolotto, A.1    Gilli, F.2    Sala, A.3
  • 9
    • 0023765154 scopus 로고
    • Gonadotropin-releasing hormone (GnRH) antibodies formation in hypogonadotropic azoospermic men treated with pulsatile GnRH: Diagnosis and possible alternative treatment
    • Blumenfeld Z, Frisch L, Conn PM (1988). Gonadotropin-releasing hormone (GnRH) antibodies formation in hypogonadotropic azoospermic men treated with pulsatile GnRH: diagnosis and possible alternative treatment. Fertil Steril 50:622-629.
    • (1988) Fertil Steril , vol.50 , pp. 622-629
    • Blumenfeld, Z.1    Frisch, L.2    Conn, P.M.3
  • 10
    • 0037075272 scopus 로고    scopus 로고
    • Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin
    • Casadevall N, Nataf J, Viron B et al. (2002). Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475.
    • (2002) N Engl J Med , vol.346 , pp. 469-475
    • Casadevall, N.1    Nataf, J.2    Viron, B.3
  • 11
    • 0026659050 scopus 로고
    • IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency
    • Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS (1992). IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 89:1643-1651.
    • (1992) J Clin Invest , vol.89 , pp. 1643-1651
    • Chaffee, S.1    Mary, A.2    Stiehm, E.R.3    Girault, D.4    Fischer, A.5    Hershfield, M.S.6
  • 12
    • 0037180468 scopus 로고    scopus 로고
    • A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS
    • Clanet M, Radue EW, Kappos L et al. (2002). A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 59:1507-1517.
    • (2002) Neurology , vol.59 , pp. 1507-1517
    • Clanet, M.1    Radue, E.W.2    Kappos, L.3
  • 13
    • 0021024367 scopus 로고
    • Development of anti-human chorionic gonadotropin antibodies in patients with hypogonadotropic hypogonadism. A study of four patients
    • Claustrat B, David L, Faure A, Francois R (1983). Development of anti-human chorionic gonadotropin antibodies in patients with hypogonadotropic hypogonadism. A study of four patients. J Clin Endocrinol Metab 57:1041-1047.
    • (1983) J Clin Endocrinol Metab , vol.57 , pp. 1041-1047
    • Claustrat, B.1    David, L.2    Faure, A.3    Francois, R.4
  • 14
    • 0035949741 scopus 로고    scopus 로고
    • Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients
    • Cook SD, Quinless JR, Jotkowitz A, Beaton P and the Neutralizing Antibody Study Group (2001). Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology 57:1080-1084.
    • (2001) Neurology , vol.57 , pp. 1080-1084
    • Cook, S.D.1    Quinless, J.R.2    Jotkowitz, A.3    Beaton, P.4
  • 15
    • 0032893876 scopus 로고    scopus 로고
    • Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies
    • Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T (1999). Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52:1239-1243.
    • (1999) Neurology , vol.52 , pp. 1239-1243
    • Deisenhammer, F.1    Reindl, M.2    Harvey, J.3    Gasse, T.4    Dilitz, E.5    Berger, T.6
  • 16
    • 0032494792 scopus 로고    scopus 로고
    • Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
    • European Study Group on Interferon β-1b in Secondary Progressive MS (1998). Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497.
    • (1998) Lancet , vol.352 , pp. 1491-1497
  • 17
    • 0027946071 scopus 로고
    • Neutralizing interferon β antibodies in melanoma patients treated with recombinant and natural interferon β
    • Fierlbeck G, Schreiner T, Schaber B, Walser A, Rassner G (1994). Neutralizing interferon β antibodies in melanoma patients treated with recombinant and natural interferon β. Cancer Immunol Immunother 39:263-268.
    • (1994) Cancer Immunol Immunother , vol.39 , pp. 263-268
    • Fierlbeck, G.1    Schreiner, T.2    Schaber, B.3    Walser, A.4    Rassner, G.5
  • 19
    • 0024402892 scopus 로고
    • Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukemia: Dose dependency of response and frequency of neutralizing anti-interferon antibodies
    • Freund M, von Wussow P, Diedrich H et al. (1989). Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 72:350-356.
    • (1989) Br J Haematol , vol.72 , pp. 350-356
    • Freund, M.1    Von Wussow, P.2    Diedrich, H.3
  • 20
    • 0027981534 scopus 로고
    • Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-α) during therapy for chronic hepatitis C
    • Giannelli G, Antonelli G, Fera G et al. (1994). Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-α) during therapy for chronic hepatitis C. Clin Exp Immunol 97:4-9.
    • (1994) Clin Exp Immunol , vol.97 , pp. 4-9
    • Giannelli, G.1    Antonelli, G.2    Fera, G.3
  • 22
    • 2442628195 scopus 로고    scopus 로고
    • Epitope specificity of neutralizing antibodies against IFN-beta
    • Gneiss C, Reindl M, Berger T et al. (2004). Epitope specificity of neutralizing antibodies against IFN-beta. J Interferon Cytokine Res 24:284-290.
    • (2004) J Interferon Cytokine Res , vol.24 , pp. 284-290
    • Gneiss, C.1    Reindl, M.2    Berger, T.3
  • 23
    • 0028350201 scopus 로고
    • Neutralizing antibodies against salmon calcitonin. The cause of a treatment failure in Paget's disease
    • Grauer A, Frank-Raue K, Schroth J, Raue F, Ziegler R (1994). Neutralizing antibodies against salmon calcitonin. The cause of a treatment failure in Paget's disease. Dtsch Med Wochenschr 119:507-510.
    • (1994) Dtsch Med Wochenschr , vol.119 , pp. 507-510
    • Grauer, A.1    Frank-Raue, K.2    Schroth, J.3    Raue, F.4    Ziegler, R.5
  • 24
    • 0002145306 scopus 로고    scopus 로고
    • Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis
    • Herndon RM, Jacobs LD, Coats ME et al. (1999). Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MSCare 2:1-6 (available at: http://www.mscare.org, accessed November 22, 2002).
    • (1999) Int J MSCare , vol.2 , pp. 1-6
    • Herndon, R.M.1    Jacobs, L.D.2    Coats, M.E.3
  • 25
    • 0030803840 scopus 로고    scopus 로고
    • Interferon immunogenicity: Technical evaluation of interferon-α2a
    • Hochuli E (1997). Interferon immunogenicity: technical evaluation of interferon-α2a. J Interferon Cytokine Res 17:S15-S21.
    • (1997) J Interferon Cytokine Res , vol.17
    • Hochuli, E.1
  • 26
    • 0008678962 scopus 로고    scopus 로고
    • Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
    • Jacobs LD, Cookfair DL, Rudick RA et al. (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294.
    • (1996) Ann Neurol , vol.39 , pp. 285-294
    • Jacobs, L.D.1    Cookfair, D.L.2    Rudick, R.A.3
  • 27
    • 0034727059 scopus 로고    scopus 로고
    • Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
    • Jacobs LD, Beck RW, Simon JH et al. (2000). Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898-904.
    • (2000) N Engl J Med , vol.343 , pp. 898-904
    • Jacobs, L.D.1    Beck, R.W.2    Simon, J.H.3
  • 29
    • 0029082566 scopus 로고
    • Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
    • Johnson KP, Brooks BR, Cohen JA et al. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268-1276.
    • (1995) Neurology , vol.45 , pp. 1268-1276
    • Johnson, K.P.1    Brooks, B.R.2    Cohen, J.A.3
  • 30
    • 6844254570 scopus 로고    scopus 로고
    • Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
    • Johnson KP, Brooks BR, Cohen JA et al. (1998). Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50:701-708.
    • (1998) Neurology , vol.50 , pp. 701-708
    • Johnson, K.P.1    Brooks, B.R.2    Cohen, J.A.3
  • 31
    • 0034455447 scopus 로고    scopus 로고
    • Neutralizing and binding anti-interferon-β (IFN-β) antibodies. A comparison between IFN-β-1a and IFN-β-1b treatment in multiple sclerosis
    • Kivisäkk P, Aim GV, Fredrikson S, Link H (2000). Neutralizing and binding anti-interferon-β (IFN-β) antibodies. A comparison between IFN-β-1a and IFN-β-1b treatment in multiple sclerosis. Eur J Neurol 7:27-34.
    • (2000) Eur J Neurol , vol.7 , pp. 27-34
    • Kivisäkk, P.1    Aim, G.V.2    Fredrikson, S.3    Link, H.4
  • 32
    • 17644436776 scopus 로고
    • Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: Pilot study analysis and six-year follow-up
    • Knobler RL, Greenstein JI, Johnson KP et al. (1993). Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 13:333-340.
    • (1993) J Interferon Res , vol.13 , pp. 333-340
    • Knobler, R.L.1    Greenstein, J.I.2    Johnson, K.P.3
  • 33
    • 0006511559 scopus 로고
    • Assessment of the antigenic response in humans to a recombinant mutant interferon beta
    • Konrad MW, Childs AL, Merigan TC, Borden EC (1987). Assessment of the antigenic response in humans to a recombinant mutant interferon beta. J Clin Immunol 7:365-375.
    • (1987) J Clin Immunol , vol.7 , pp. 365-375
    • Konrad, M.W.1    Childs, A.L.2    Merigan, T.C.3    Borden, E.C.4
  • 35
    • 0025607230 scopus 로고
    • Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection
    • Lok AS-F, Lai C-L, Leung EK-Y (1990). Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 12:1266-1270.
    • (1990) Hepatology , vol.12 , pp. 1266-1270
    • Lok, A.S.-F.1    Lai, C.-L.2    Leung, E.K.-Y.3
  • 36
    • 0028122001 scopus 로고
    • Human antibodies to recombinant factor VIII in hemophiliacs
    • Lusher JM (1994). Human antibodies to recombinant factor VIII in hemophiliacs. J Interferon Res 14:173-174.
    • (1994) J Interferon Res , vol.14 , pp. 173-174
    • Lusher, J.M.1
  • 37
    • 0033935277 scopus 로고    scopus 로고
    • Inhibitor antibodies to factor VIII and factor IX: Management
    • Lusher JM (2000). Inhibitor antibodies to factor VIII and factor IX: management. Sem Thromb Hemost 26:179-188.
    • (2000) Sem Thromb Hemost , vol.26 , pp. 179-188
    • Lusher, J.M.1
  • 38
    • 0027473752 scopus 로고
    • Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors
    • Lusher JM, Arkin S, Abildgaard CF, Schwartz RS and the Kogenate Previously Untreated Patient Study Group (1993). Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. N Engl J Med 328:453-459.
    • (1993) N Engl J Med , vol.328 , pp. 453-459
    • Lusher, J.M.1    Arkin, S.2    Abildgaard, C.F.3    Schwartz, R.S.4
  • 39
    • 0028104092 scopus 로고
    • Human antibodies to insulin in diabetes
    • Meager A (1994). Human antibodies to insulin in diabetes. J Interferon Res 14:181-182.
    • (1994) J Interferon Res , vol.14 , pp. 181-182
    • Meager, A.1
  • 40
    • 0018974918 scopus 로고
    • Role of aggregated human growth hormone (hGH) in development of antibodies to hGH
    • Moore WV, Leppert P (1980). Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51:691-697.
    • (1980) J Clin Endocrinol Metab , vol.51 , pp. 691-697
    • Moore, W.V.1    Leppert, P.2
  • 41
    • 0023933922 scopus 로고
    • Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII
    • Nilsson IM, Berntorp E, Zettervall O (1988). Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 318:947-950.
    • (1988) N Engl J Med , vol.318 , pp. 947-950
    • Nilsson, I.M.1    Berntorp, E.2    Zettervall, O.3
  • 42
    • 0024523620 scopus 로고
    • Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: Development of neutralizing interferon antibodies and possible loss of antitumor activity
    • Oberg K, Alm G, Magnusson A et al. (1989). Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 81:531-535.
    • (1989) J Natl Cancer Inst , vol.81 , pp. 531-535
    • Oberg, K.1    Alm, G.2    Magnusson, A.3
  • 43
    • 33644571906 scopus 로고    scopus 로고
    • Comparison of the dose effects of three commercially available β-interferons on in vitro immune function in controls and multiple sclerosis patients
    • Abstract
    • Oger J, Al-Fahim A, Aziz T, Wang L (2000). Comparison of the dose effects of three commercially available β-interferons on in vitro immune function in controls and multiple sclerosis patients. Ann Neurol 48:476 (Abstract).
    • (2000) Ann Neurol , vol.48 , pp. 476
    • Oger, J.1    Al-Fahim, A.2    Aziz, T.3    Wang, L.4
  • 44
    • 0035863468 scopus 로고    scopus 로고
    • Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
    • Olsen E, Duvic M, Frankel A et al. (2001). Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376-388.
    • (2001) J Clin Oncol , vol.19 , pp. 376-388
    • Olsen, E.1    Duvic, M.2    Frankel, A.3
  • 45
    • 0037180479 scopus 로고    scopus 로고
    • Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE Trial
    • Panitch H, Goodin DS, Francis G et al. for the Evidence of Interferon Dose-Response: European North American Comparative Efficacy (EVIDENCE) Study Group and the University of British Columbia MS/MRI Research Group (2002). Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE Trial. Neurology 59:1496-1506.
    • (2002) Neurology , vol.59 , pp. 1496-1506
    • Panitch, H.1    Goodin, D.S.2    Francis, G.3
  • 46
    • 0029759027 scopus 로고    scopus 로고
    • Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia
    • Peces R, de la Torre M, Alcázar R, Urra JM (1996). Antibodies against recombinant human erythropoietin in a patient with erythropoietin- resistant anemia. N Engl J Med 335:523-524.
    • (1996) N Engl J Med , vol.335 , pp. 523-524
    • Peces, R.1    De La Torre, M.2    Alcázar, R.3    Urra, J.M.4
  • 47
    • 0034744952 scopus 로고    scopus 로고
    • Interferon-beta (IFN-β) antibodies in interferon-β1a- and interferon-β1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo
    • Perini P, Facchinetti A, Bulian P et al. (2001). Interferon-beta (IFN-β) antibodies in interferon-β1a- and interferon-β1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo. Eur Cytokine Netw 12:56-61.
    • (2001) Eur Cytokine Netw , vol.12 , pp. 56-61
    • Perini, P.1    Facchinetti, A.2    Bulian, P.3
  • 48
    • 0037435532 scopus 로고    scopus 로고
    • Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b
    • Polman C, Kappos L, White R et al. (2003). Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b. Neurology 60:37-43.
    • (2003) Neurology , vol.60 , pp. 37-43
    • Polman, C.1    Kappos, L.2    White, R.3
  • 49
    • 0024563550 scopus 로고
    • Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon
    • Porres JC, Carreno V, Ruíz M, Marrón JA, Bartolomé J (1989). Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatol 8:351-357.
    • (1989) J Hepatol , vol.8 , pp. 351-357
    • Porres, J.C.1    Carreno, V.2    Ruíz, M.3    Marrón, J.A.4    Bartolomé, J.5
  • 50
    • 0036158851 scopus 로고    scopus 로고
    • Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b: A randomized trial in multiple sclerosis
    • Pozzilli C, Antonini G, Bagnato F et al. (2002). Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b: a randomized trial in multiple sclerosis. J Neurol 249:50-56.
    • (2002) J Neurol , vol.249 , pp. 50-56
    • Pozzilli, C.1    Antonini, G.2    Bagnato, F.3
  • 51
    • 0030907535 scopus 로고    scopus 로고
    • Antibodies to recombinant human erythropoietin causing pure red cell aplasia
    • Prabhakar SS, Muhlfelder T (1997). Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 47:331-335.
    • (1997) Clin Nephrol , vol.47 , pp. 331-335
    • Prabhakar, S.S.1    Muhlfelder, T.2
  • 52
    • 0345601517 scopus 로고    scopus 로고
    • Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
    • Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group (1998). Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504.
    • (1998) Lancet , vol.352 , pp. 1498-1504
  • 53
    • 0035954361 scopus 로고    scopus 로고
    • PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS
    • Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group and the University of British Columbia MS/MRI Analysis Group (2001). PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56:1628-1636.
    • (2001) Neurology , vol.56 , pp. 1628-1636
  • 54
    • 0000288456 scopus 로고
    • The antigenicity of insulin: A review
    • Prout TE (1962). The antigenicity of insulin: a review. J Chronic Dis 15:879-885.
    • (1962) J Chronic Dis , vol.15 , pp. 879-885
    • Prout, T.E.1
  • 55
    • 0030841117 scopus 로고    scopus 로고
    • Treatment-induced antibodies to interleukin-2
    • Prümmer O (1997). Treatment-induced antibodies to interleukin-2. Biotherapy 10:15-24.
    • (1997) Biotherapy , vol.10 , pp. 15-24
    • Prümmer, O.1
  • 56
    • 2442743850 scopus 로고    scopus 로고
    • A novel bioassay for the determination of neutralizing antibodies to IFN-β-1b
    • Pungor Jr E, Files JG, Gabe JD et al. (1998). A novel bioassay for the determination of neutralizing antibodies to IFN-β-1b. J Interferon Cytokine Res 18:1025-1030.
    • (1998) J Interferon Cytokine Res , vol.18 , pp. 1025-1030
    • Pungor Jr., E.1    Files, J.G.2    Gabe, J.D.3
  • 57
    • 0022359745 scopus 로고
    • Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma
    • Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU (1985). Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3:1522-1528.
    • (1985) J Clin Oncol , vol.3 , pp. 1522-1528
    • Quesada, J.R.1    Rios, A.2    Swanson, D.3    Trown, P.4    Gutterman, J.U.5
  • 58
    • 0030438946 scopus 로고    scopus 로고
    • Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy
    • Ragnhammar P, Wadhwa M (1996). Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy. Med Oncol 13:161-166.
    • (1996) Med Oncol , vol.13 , pp. 161-166
    • Ragnhammar, P.1    Wadhwa, M.2
  • 59
    • 0025898683 scopus 로고
    • Antibodies that neutralize human β interferon biologic activity recognize a linear epitope: Analysis by synthetic peptide mapping
    • Redlich PN, Hoeprich Jr PD, Colby CB, Grossberg SE (1991). Antibodies that neutralize human β interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping. Proc Natl Acad Sci USA 88:4040-4044.
    • (1991) Proc Natl Acad Sci USA , vol.88 , pp. 4040-4044
    • Redlich, P.N.1    Hoeprich Jr., P.D.2    Colby, C.B.3    Grossberg, S.E.4
  • 60
    • 0031920770 scopus 로고    scopus 로고
    • Natural and therapeutically-induced antibodies to cytokines
    • Revoltella RP (1998). Natural and therapeutically-induced antibodies to cytokines. Biotherapy 10:321-331.
    • (1998) Biotherapy , vol.10 , pp. 321-331
    • Revoltella, R.P.1
  • 61
    • 0032893144 scopus 로고    scopus 로고
    • The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b
    • Rice GPA, Paszner B, Oger J, Lesaux J, Paty D, Ebers G (1999). The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b. Neurology 52:1277-1279.
    • (1999) Neurology , vol.52 , pp. 1277-1279
    • Rice, G.P.A.1    Paszner, B.2    Oger, J.3    Lesaux, J.4    Paty, D.5    Ebers, G.6
  • 62
    • 33644581548 scopus 로고    scopus 로고
    • Further evidence of dose effect of IFN beta-1a based on neutralizing antibody status. (poster presentation) April 21-25, 2001; Paris, France
    • Rice GPA, Francis GS and the PRISMS Study Group (2001). Further evidence of dose effect of IFN beta-1a based on neutralizing antibody status. 11th Annual Meeting of the European Neurological Society (poster presentation) April 21-25, 2001; Paris, France.
    • (2001) 11th Annual Meeting of the European Neurological Society
    • Rice, G.P.A.1    Francis, G.S.2
  • 63
    • 0025943513 scopus 로고
    • Streptokinase immunogenicity in thrombolytic therapy for acute myocardial infarction
    • Rosenschein U, Lenz R, Radnay J, Ben Tovim T, Rozenszajn LA (1991). Streptokinase immunogenicity in thrombolytic therapy for acute myocardial infarction. Isr J Med Sci 27:541-545.
    • (1991) Isr J Med Sci , vol.27 , pp. 541-545
    • Rosenschein, U.1    Lenz, R.2    Radnay, J.3    Ben Tovim, T.4    Rozenszajn, L.A.5
  • 64
    • 0033763507 scopus 로고    scopus 로고
    • Immunogenicity of interferon-β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration
    • Ross C, Clemmesen KM, Svenson M et al. (2000). Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 48:706-712.
    • (2000) Ann Neurol , vol.48 , pp. 706-712
    • Ross, C.1    Clemmesen, K.M.2    Svenson, M.3
  • 65
    • 0034853968 scopus 로고    scopus 로고
    • Short-term brain volume change in relapsing-remitting multiple sclerosis. Effect of glatiramer acetate and implications
    • Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M; European/Canadian Glatiramer Acetate Study Group (2001). Short-term brain volume change in relapsing-remitting multiple sclerosis. Effect of glatiramer acetate and implications. Brain 124:1803-1812.
    • (2001) Brain , vol.124 , pp. 1803-1812
    • Rovaris, M.1    Comi, G.2    Rocca, M.A.3    Wolinsky, J.S.4    Filippi, M.5
  • 66
    • 0031841745 scopus 로고    scopus 로고
    • Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
    • Rudick RA, Simonian NA, Alam JA et al. (1998). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50:1266-1272.
    • (1998) Neurology , vol.50 , pp. 1266-1272
    • Rudick, R.A.1    Simonian, N.A.2    Alam, J.A.3
  • 67
    • 14444271579 scopus 로고    scopus 로고
    • Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β)
    • Runkel L, Meier W, Pepinsky RB et al. (1998). Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm Res 15:641-649.
    • (1998) Pharm Res , vol.15 , pp. 641-649
    • Runkel, L.1    Meier, W.2    Pepinsky, R.B.3
  • 68
    • 0036598634 scopus 로고    scopus 로고
    • Bioequivalence and the immunogenicity of biopharmaceuticals
    • Schellekens H (2002). Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev 1:457-462.
    • (2002) Nat Rev , vol.1 , pp. 457-462
    • Schellekens, H.1
  • 69
    • 0027519426 scopus 로고
    • Immunogenicity and allergenic potential of animal and human insulins
    • Schernthaner G (1993). Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16:155-165.
    • (1993) Diabetes Care , vol.16 , pp. 155-165
    • Schernthaner, G.1
  • 70
    • 10744225329 scopus 로고    scopus 로고
    • Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
    • Sorensen PS, Ross C, Clemmesen KM et al. (2003). Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184-1991.
    • (2003) Lancet , vol.362 , pp. 1184-1991
    • Sorensen, P.S.1    Ross, C.2    Clemmesen, K.M.3
  • 71
    • 0023893064 scopus 로고
    • Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies
    • Steis RG, Smith II JW, Urba WJ et al. (1988). Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318:1409-1413.
    • (1988) N Engl J Med , vol.318 , pp. 1409-1413
    • Steis, R.G.1    Smith II, J.W.2    Urba, W.J.3
  • 72
    • 0027418515 scopus 로고
    • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
    • The IFNB Multiple Sclerosis (IFNB MS) Study Group (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661.
    • (1993) Neurology , vol.43 , pp. 655-661
  • 73
    • 0005489101 scopus 로고    scopus 로고
    • Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
    • The IFNB Multiple Sclerosis (IFNB MS) Study Group and the University of British Columbia MS/MRI Analysis Group (1996). Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47:889-894.
    • (1996) Neurology , vol.47 , pp. 889-894
  • 74
    • 0344809968 scopus 로고    scopus 로고
    • Evidence of interferon β-1a dose response in relapsing-remitting MS
    • The Once Weekly Interferon for MS (OWIMS) Study Group (1999). Evidence of interferon β-1a dose response in relapsing-remitting MS. Neurology 53:679-686.
    • (1999) Neurology , vol.53 , pp. 679-686
  • 75
    • 0037172854 scopus 로고    scopus 로고
    • Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients
    • Vallittu A-M, Halminen M, Peltoniemi J et al. (2002). Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology 58:1786-1790.
    • (2002) Neurology , vol.58 , pp. 1786-1790
    • Vallittu, A.-M.1    Halminen, M.2    Peltoniemi, J.3
  • 76
    • 0027998387 scopus 로고
    • On the immunogenicity of recombinant staphylokinase in patients and in animal models
    • Vanderschueren SMF, Stassen JM, Collen D (1994). On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb Haemost 72:297-301.
    • (1994) Thromb Haemost , vol.72 , pp. 297-301
    • Vanderschueren, S.M.F.1    Stassen, J.M.2    Collen, D.3
  • 80
    • 0038631638 scopus 로고    scopus 로고
    • Zipkin I (1998). Amgen Lays MGDF to Rest. BioCentury website (available at: http://www.biocentury.com/, accessed April 29, 2002).
    • (1998) Amgen Lays MGDF to Rest
    • Zipkin, I.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.